underwriting and dealing to a limited extent in all types of equity securities, other than ownership interest in open-end investment companies; making, acquiring and servicing loans and other extensions of credit, pursuant to § 225.28(b)(1) of Regulation Y; providing investment and financial advisory services, pursuant to § 225.28(b)(6) of Regulation Y; arranging commercial or industrial real estate equity financing, pursuant to § 225.28(b)(2)(ii) of Regulation Y; underwriting and dealing in obligations of the United States and Canada, general obligations of U.S. States, Canadian provinces, and their political subdivisions, and other obligations in which state member banks may underwrite and deal under 12 U.S.C. 24 and 335, pursuant to § 225.28(b)(8) of Regulation Y; and providing securities brokerage, private placement, and riskless principal services, pursuant to § 225.28(b)(7)(i), (ii), (iii) and (iv) of Regulation Y. The proposed activities are currently being conducted, directly or indirectly, by the subject entities with Board approval.


Robert deV. Frierson, Associate Secretary of the Board.
[FR Doc. 98–17453 Filed 6–30–98; 8:45 am]
BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct; Terry D. Reisine, Ph.D.

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Terry D. Reisine, Ph.D., University of Pennsylvania: Based upon “The Dean’s Proposed Findings of Fact” and “Memorandum on Issues Not Fully Addressed in Findings of Fact,” forwarded to ORI by the University of Pennsylvania, dated October 25, 1996 (Findings and Memorandum), and ORI’s oversight review of the evidence provided, ORI finds that Terry D. Reisine, Ph.D., former Professor, Department of Pharmacology, University of Pennsylvania, engaged in scientific misconduct in biomedical research supported by Public Health Service (PHS) grants.

Specifically, ORI finds that the Respondent falsified results related to the measurement of cyclic AMP in cultured, transfected cells by falsely representing in manuscripts and publications the number of experiments conducted, and by falsifying and/or fabricating some of the substantive data presented in those manuscripts and publications. Moreover, ORI finds that the Respondent attempted to falsify data by directing members of his laboratory to construct figures and tables with false values in the preparation of manuscripts.

Dr. Reisine has entered into a Voluntary Exclusion Agreement with ORI. The settlement is not an admission of liability on the part of the Respondent, and Dr. Reisine denies having committed scientific misconduct. Pursuant to the Agreement, Dr. Reisine has agreed to the following:

(1) Respondent agreed to exclude himself voluntarily for a period of three (3) years beginning on June 11, 1998, from any contracting or subcontracting with any agency of the United States Government, and from eligibility for or involvement in nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR part 76 (Debarment Regulations).

(2) Respondent agreed to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on June 11, 1998.

(3) Within 30 days of the effective date of the Agreement, Respondent agreed to submit to the following journals requesting correction of the corresponding articles. The corrections are warranted by the following findings of the Findings and Memorandum:

a. The Journal of Biological Chemistry


(1) The results in Table 1 are stated in the table legend to be based on four (4) experiments with calculated SEM values and Hill coefficients when, in fact, the majority of the listed compounds were tested only once, and a few tested only twice.

(2) Figure 2 data are stated in the figure legend to be the means of three (3) different experiments when, in fact, most of the results were based on a single experiment.

b. The Journal of Pharmacology and Experimental Therapeutics


(1) The figure legend for Figures 3A, 3C, and 3D claimed that the values shown were the average of three (3) different experiments when, in fact, the results were from only one (1) experiment.

(2) The figure legend for Figure 4B claimed that the values shown were the average of four (4) different experiments when, in fact, the results were from only three (3) experiments.

(3) Figures 3A, 3C, and 3D each show several levels of adenyl cyclase inhibition that do not reflect the actual results obtained in duplicate cyclic AMP assays.

c. Molecular Pharmacology


(1) The legend for Figure 3A claims that three (3) experiments were performed when, in fact, only two (2) experiments were performed for the SST2B mutants.

(2) The legend for Figure 3B claims that the values presented are the average of two (2) different experiments when, in fact, the inhibition curve shown was based on a single experiment.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Dorothy K. Macfarlane, Acting Director, Office of Research Integrity.
[FR Doc. 98–17411 Filed 6–30–98; 8:45 am]
BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Program Announcement 98095]

Enhancement of Local Public Health Departments Participation in Brownfields Decisions and Actions; Notice of Availability of Funds

Introduction

The Agency for Toxic Substances and Disease Registry (ATSDR) announces the availability of fiscal year (FY) 1998 funds for a cooperative agreement program for a pilot activity with a select number of local health departments to demonstrate effective public health